Comparing Camu Camu With Combination Nivolumab and Ipilimumab for mRCC

Regina Barragán-Carrillo, MD, City of Hope, provides an overview of her recent research evaluating the difference between treatment with nivolumab and ipilimumab versus extract from the comestible camu camu berry in patients with mRCC.

Dr. Barragán-Carrillo explains the role of the gut microbiome in modulating clinical responses and the potential benefits of camu camu in reducing tumor size.